Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Contract Manufacturing Services, Small Molecules, Trends & Forecasts

Why Small Molecules Are Still a Big Deal

In 2018, major news included Abbvie’s Humira, a monoclonal antibody (mAb) approved for the treatment of arthritis and a range of diseases in the inflammation and immunology space, leading the pack of global highest-revenue drugs with sales of around $20 billion. In addition, innovative cell and gene therapies seem ready to revolutionize treatment for diseases from sickle-cell anemia to inherited genetic forms of blindness; the FDA expects to approve 10–20 cell and gene therapy products a year by 2025.

But scratch beneath the surface and you’ll see that biologics are not the only big players in the pharma space. Small molecules continue to play a significant role in the development of innovative treatments that benefit the lives of patients around the world. Specialty medicines are increasingly driving global pharma growth, especially in developed markets, with approximately half of specialty sales attributable to small molecule applications.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Gordon Bates

President, Chemical Division, Lonza Pharma & Biotech

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register